Marcel André Schneider

Marcel André Schneider

Auto-generated profile, based on publicly available information

Marcel André Schneider

Department of Visceral and Transplant Surgery, University Hospital Zurich , Zurich

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
MSMarcel André Schneider
Marcel André Schneider
LHLaura Heeb
Laura Heeb
MBMichal Mateusz Beffinger
Michal Mateusz Beffinger
SPStanislav Pantelyushin
Stanislav Pantelyushin
MLMichael Linecker
Michael Linecker
PCPierre-Alain Clavien
Pierre-Alain Clavien
Serotonin dampens tumor-specific immunity in pancreatic and colorectal cancer mouse models.

1 November 2018 in HPB
Verified
Journal Article
Closed access
DEDilmurodjon Eshmuminov
Dilmurodjon Eshmuminov
MSMarcel A. Schneider
Marcel A. Schneider
CTChristoph Tschuor
Christoph Tschuor
DRDimitri A. Raptis
Dimitri A. Raptis
PKPatryk Kambakamba
Patryk Kambakamba
PCPierre-Alain Clavien
Pierre-Alain Clavien

1 November 2018 in Annals of Surgery
Verified
Journal Article
Closed access
MSMarcel André Schneider
Marcel André Schneider
JEJanina Eden
Janina Eden
Basile PacheBasile Pache
Basile Pache
FLFelix Laminger
Felix Laminger
VLVictor Lopez-Lopez
Victor Lopez-Lopez
KLKuno Lehmann
Kuno Lehmann
Background: Adequate selection of patients with peritoneal metastasis (PM) for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) remains critical for successful long-term outcomes. Factors reflecting tumor biology are currently poorly represented in the selection process. The prognostic relevance of RAS/RAF mutations in patients with PM remains unclear. Methods: Survival data of patients with colorectal PM operated in 6 European tertiary centers were retrospectively collected and predictive factors for survival identified by Cox regression analyses. A simple point-based risk score was developed to allow patient selection and outcome prediction. Results: Data of 524 patients with a median age of 59 years and a median peritoneal cancer index of 7 (interquartile range: 3–12) were collected. A complete resection was possible in 505 patients; overall morbidity and 90-day mortality were 50.9% and 2.1%, respectively. PCI [hazard ratio (HR): 1.08], N1 stage (HR: 2.15), N2 stage (HR: 2.57), G3 stage (HR: 1.80) as well as KRAS (HR: 1.46) and BRAF (HR: 3.97) mutations were found to significantly impair survival after CRS/HIPEC on multivariate analyses. Mutations of RAS/RAF impaired survival independently of targeted treatment against EGFR. Consequently, a simple point-based risk score termed BIOSCOPE (BIOlogical Score of COlorectal PEritoneal metastasis) based on PCI, N-, G-, and RAS/RAF status was developed, which showed good discrimination [development area under the curve (AUC) = 0.72, validation AUC = 0.70], calibration (P = 0.401) and allowed categorization of patients into 4 groups with strongly divergent survival outcomes. Conclusion: RAS/RAF mutations impair survival after CRS/HIPEC. The novel BIOSCOPE score reflects tumor biology, adequately stratifies long-term outcomes, and improves patient assessment and selection.

23 January 2021 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
EBEva Breuer
Eva Breuer
MHMonika Hebeisen
Monika Hebeisen
MSMarcel André Schneider
Marcel André Schneider
LRLilian Roth
Lilian Roth
CPChantal Pauli
Chantal Pauli
KLKuno Lehmann
Kuno Lehmann
Multimodal treatment, including systemic treatment and surgery, improved the prognosis of peritoneal metastasis (PM). Despite all efforts, recurrence rates remain high, and little data are available about clinical behavior or molecular patterns of PM in comparison to hematogenous metastasis. Here, we aimed to analyze recurrence patterns after multimodal treatment for PM from colorectal cancer. Patients with colorectal PM undergoing multimodal treatment including systemic chemotherapy and cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) between 2005 and 2017 at 4 centers were analyzed retrospectively. A total of 505 patients undergoing CRS/HIPEC were analyzed. Of the patients, 82.1% received preoperative chemotherapy. Median peritoneal cancer index was 6 (interquartile range = 3-11). Median disease-free and overall survival was 12 (95% confidence interval [CI] = 11 to 14) months and 51 (95% CI = 43 to 62) months, respectively. Disease recurred in 361 (71.5%) patients, presenting as isolated peritoneal recurrence in 24.6%, isolated hematogenous recurrence in 28.3%, and mixed recurrence in 13.9% of patients. Recurrence to the peritoneum was associated with an impaired time from recurrence to death of 21 (95% CI = 18 to 31) months for isolated peritoneal and 22 (95% CI = 16 to 30) months for mixed recurrence, compared with 43 (95% CI = 31 to >121) months for hematogenous recurrence (hazard ratio [HR] = 1.79, 95% CI = 1.27 to 2.53; P = .001; and HR = 2.44, 95% CI = 1.61 to 3.79; P < .001). On multiple logistic regression analysis, RAS mutational status (odds ratio [OR] = 2.42, 95% CI = 1.11 to 5.47; P = .03) and positive nodal stage of the primary (OR = 3.88, 95% CI = 1.40 to 11.86; P = .01) were identified as predictive factors for peritoneal recurrence. This study highlights the heterogeneity of peritoneal metastasis in patients with colorectal cancer. Recurrent peritoneal metastasis after radical treatment represents a more aggressive subset of metastatic colorectal cancer.
1

1 February 2017 in Surgery
Verified
Journal Article
Closed access
MLMichael Linecker
Michael Linecker
PKPatryk Kambakamba
Patryk Kambakamba
CRCäcilia S. Reiner
Cäcilia S. Reiner
TNThi Dan Linh Nguyen-Kim
Thi Dan Linh Nguyen-Kim
GSGregor A. Stavrou
Gregor A. Stavrou
HPHenrik Petrowsky
Henrik Petrowsky

6 March 2017 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
MSMarcel André Schneider
Marcel André Schneider
DEDilmurodjon Eshmuminov
Dilmurodjon Eshmuminov
KLKuno Lehmann
Kuno Lehmann